These funds could help you build wealth over the long term. The post How to build wealth with ASX ETFs appeared first on The ...

The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment analysis.

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Novo Nordisk plans "all in" launch of Wegovy pill Novo Nordisk cuts U.S. price of injectable Wegovy Price will go down to $349 per month ahead of schedule CEO Doustdar highlights consumer weight-loss ...

Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the progress of Alzheimer's disease. Novo ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...

Novo Nordisk has lost ground in the weight-loss drug market to Eli Lilly and telehealth companies. The company's new CEO is being far more aggressive, which bodes well. Novo's upcoming Wegovy pill is ...

GLP-1 weight loss drugs are still far from cheap, but some of the prices keep dropping. Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and ...